Shares of Zai Lab Ltd (09688) surged more than 7% during trading on Tuesday, driven by strong second-quarter earnings and positive analyst commentary. As of the latest update, the stock was trading 5.68% higher at HK$18.60, with turnover reaching HK$185 million.

The company recently released its financial results for the second quarter of 2026, highlighting key product performance and corporate developments. Total revenue for the period reached US$106.3 million, with net product revenue of US$105.8 million, marking an 11% sequential increase from the previous quarter. This growth was supported by stable sales of Zejula and continued momentum in VYVGART sales.

Dr. Samantha Du, Founder and CEO of Zai Lab, stated that the company is evolving into a global biopharmaceutical firm focused on developing differentiated therapies for patients worldwide. Citigroup analysts noted in a report that the 11% quarter-over-quarter improvement in product revenue to approximately US$106 million aligned with both their estimates and market expectations, reinforcing confidence that the company's China operations will stabilize in the second half of 2026 and return to significant growth by 2027, as per management guidance. The investment bank also highlighted growing attention on upcoming pipeline catalysts, with zoci remaining a key value driver.